Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adults With Overweight or Obesity (STEP 1)

John P.H. Wilding1; Rachel L. Batterham2; Melanie Davies3; Luc F. Van Gaal4; Ildiko Lingvay5; Barbara M. McGowan6; Tugce K. Oral7; Julio Rosenstock8; Marie T.D. Tran7; Thomas Wadden9; Sean Wharton10; Koutaro Yokote11; Niels Zeuthen7; Robert F. Kushner12;
1Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; 2University College London and National Institute of Health Research, UCLH Biomedical Research Centre and Centre for Weight Management and Metabolic Surgery, UCLH, London, UK; 3University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK; 4Antwerp University Hospital, University of Antwerp, Belgium; 5UT Southwestern Medical Center, Dallas, TX, USA; 6Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 7Novo Nordisk A/S, Søborg, Denmark; 8Dallas Diabetes Research Center at Medical City, Dallas, TX, USA; 9University of Pennsylvania, Philadelphia, PA, USA; 10York University, McMaster University and Wharton Weight Management Clinic, Toronto, ON, Canada; 11Chiba University and Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan; 12Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.;